93 results about "Ovarian carcinomas" patented technology

The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and / or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.

Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase / compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.

Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.

The invention discloses a BRCA gene susceptibility SNP locus detection composition. The BRCA gene susceptibility SNP locus detection composition comprises a primer of SEQ NO:1-SEQ NO:448. The BRCA gene susceptibility SNP locus detection composition has the advantages that more than two thousand susceptibility SNP loci of a BRCA gene can be detected at one time, for the susceptibility SNP loci relative to breast cancer and ovarian cancer, the detection throughput is high, the specificity is strong, the pollution is not prone to occur, and the safety is high, the detection result has good accuracy and repeatability, and certain auxiliary diagnosis and implication effects are achieved for susceptible population of the breast cancer and the ovarian cancer, especially for crowd with family heredity of the two cancers.

The invention discloses a di-beta-carboline alkali compound and a preparation method, a medicinal composition and application thereof. The di-beta-carboline alkali compound and pharmaceutical salt thereof are shown as a general formula I. The di-beta-carboline alkali compound is prepared by condensing a beta-carboline intermediate and dihalogenated alkane. The medicinal composition comprises an effective dose of di-beta-carboline alkali compound shown as the formula I and a pharmacodynamically acceptable carrier. The invention also discloses application of the di-beta-carboline alkali compound to preparation of medicines for resisting tumors such as melanoma, gastric cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermal carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostatic cancer and colon cancer.

The invention provides a novel antibody that is directed towards a tumor preventing protein specific area. Based on the antibody, the diagnostic method and kit for determining the variation types of BRCA1 protein in breast or ovarian cancer are also provided.

The invention relates to a bispecific oligopeptide-lidamycin energized fusion protein Ec-LDP-Hr-AE. The fusion protein comprises two oligopeptides of targeted epidermal growth factor receptors EGFR and HER2, a lidamycin apoprotein and a lidamycin activity chromophore, and researches show that the fusion protein in vitro can be combined with the epidermal growth factor receptors EGFR and HER2 for expressing the specificities of the tumor cells, has strong damaging effect for the tumor cells and remarkable therapeutic effect for the transplanted tumor of nude mice for the ovarian cancer SK-OV-3 after the in vivo test, displays the characteristics of miniaturization and high efficiency of targeting drugs and has good application prospect.

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and / or doxorubicin are provided. Methods of administering the combinations to treat cancers, e.g., ovarian cancers, with greater clinical efficacy and / or decreased toxicity are also provided.

This invention provides compositions and methods for predicting and improving a chemotherapy response to treat an ovarian cancer. In one embodiment, the invention provides compositions and methods for detecting the expression level of Let-7i microRNA to predict a chemotherapy response. In another embodiment, the invention provides compositions and methods for enhancing the expression level of Let-7i microRNA to improve a chemotherapy response.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

The CA125 gene has been cloned and multiple repeat sequences as well as the carboxy terminus have been identified. The CA125 molecule comprises three major domains: an extracellular amino terminal domain (Domain 1); a large multiple repeat domain (Domain 2); and a carboxy terminal domain (Domain 3) which includes a transmembrane anchor with a short cytoplasmic domain. The amino terminal domain is assembled by combining five genomic exons, four very short amino terminal sequences and one extraordinarily large exon. This domain is dominated by its capacity for O-glycosylation and its resultant richness in serine and threonine residues. Additionally, an amino terminal extension is present, which comprises four genomic exons. The amino acid composition of the amino terminal extension was found to be consistent with the amino acid composition of the amino terminal domain. The molecular structure is dominated by a repeat domain comprising 156 amino acid repeat units, which encompass the epitope binding sites. More than 60 repeat units have been identified, sequenced, and contiguously placed in the CA125 domain structure. The repeat units encompass an interactive disulfide bridged C-enclosure and the site of OC125 and M11 binding. The repeat sequences demonstrated 70-85% homology to each other. Expression of the repeats was demonstrated in E. coli. The CA125 molecule is anchored at its carboxy terminal through a transmembrane domain and a short cytoplasmic tail. The carboxy terminal also contains a proteolytic cleavage site approximately 50 amino acids upstream from the transmembrane domain, which allows for proteolytic cleavage and release of the CA125 molecule. Any one of the repeat domains has the potential for use as a new gold standard for detecting and monitoring the presence of the CA125 antigen. Further, the repeat domains or other domains, especially the c-terminal to the repeat domain also provide a basis for the development of a vaccine, which would be useful for the treatment of ovarian cancer and other carcinomas where CA125 is elevated.

The invention discloses a compound having the following general formula (I), wherein K is selected from a cycloalkane group shown in the following formula. The invention also discloses an indoleamine-2,3-dioxygenase inhibitor comprising the compound and an application of the compound in preparation of drugs for treating cancer. The compound of the invention can effectively inhibit cell proliferation, has a good therapeutic effect on various diseases such as cancer, has significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer, brain cancer, skin cancer, oral cancer, prostatic cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumor, ovarian tumor, peritoneal tumor, stage IV melanoma, glioma, glioblastoma, hepatocellular carcinoma, mastoid renal tumor, head and neck tumor, leukemia, lymphoma, myeloma, non-small cell lung cancer, and the like, and has very broad application prospects.

The invention discloses a synthesis process for a Rucaparib intermediate of an ovarian cancer treating medicine. The synthesis process for the Rucaparib intermediate of the ovarian cancer treating medicine is characterized by comprising the following step that a compound as shown in the formula II is reacted under acidic conditions to obtain the Rucaparib intermediate as shown in the formula I; the synthesis process for the Rucaparib intermediate provided by the invention has fewer reaction steps, and is low in production cost, short in reaction time, high in production efficiency and more suitable for industrialized production. The intermediate prepared through the process disclosed by the invention is high in yield and purity.

The invention discloses a method for measuring the antigen of ovarian cancer embryo by an electrochemical luminescence (ECL) immunosensor. The method comprises the following steps of: producing bioactivator-carried Fe3O4 magnetic nano particles by an immune sandwich method; and modifying the particles on the surface of a solid paraffin carbon paste electrode (SCPE), developing an easily updated immunosensor, and measuring the CA125 antigen by an ECL method. Glucose is catalyzed and oxidized by glucose oxidase (GOD) to generate H2O2, and an ECL signal is generated by a Luminol. The ECL signal is observably enhanced along with the increase of the GOD-labeled second antibody concentration. The sensor is good in response to the CA125, and the linear range of the sensor is 0.01-10mU / mL. The method is high in sensitivity, good in selectivity, high in specificity, easy to update, and wide in application scope.

The invention provides a hydrophobic steroid saponin extract of peltate yam rhizome as well as a preparation method and use thereof. In the invention, in vitro anti-cancer drug experimental study proves that the hydrophobic steroid saponin extract of the peltate yam rhizome has strong growth inhibition activity on cell lines of colon cancer, lung cancer, breast cancer, cervical carcinoma, ovarian cancer, larynx cancer and the like. The extract of peltate yam rhizome has the advantages of wide resource, simple extraction and separation process of saponin, and wide prospect in cancer treatment, thus developing a new anticancer use of a hydrophobic dioscin component in the peltate yam rhizome.

The invention provides a preparation method and application of a hydrogel electrode and relates to hydrogel electrodes. The preparation method of the hydrogel electrode comprises the following steps: with graphite powder as a raw material, adding sodium nitrate, sulphuric acid and potassium hypermanganate, mixing and then carrying out reaction until a thick mixture is formed; then adding pure water for the first time, further carrying out reaction, then adding pure water for the second time and stopping reaction, then adding a hydrogen peroxide solution for removing unreacted potassium hypermanganate, washing, centrifuging, and drying, so that graphite oxide solids are obtained, and carrying out ultrasonic treatment on the graphite oxide solids, so that a uniformly dispersed graphene oxide aqueous solution is obtained; mixing the graphene oxide aqueous solution with DNA of milt, then adding the mixture into a centrifugal tube to be heated, and after gel is stably formed, inserting a copper wire into a small hole in the bottom of the centrifugal tube to be fixed, so that a graphene oxide and milt-DNA compounded hydrogel electrode is obtained. The graphene oxide and milt-DNA compounded hydrogel electrode can be used for preparing a graphene oxide and milt-DNA composite hydrogel biosensor and can be applied to detection of mutation of mitochondrial DNA of ovarian cancer.

The invention provides a general formula I compound, namely, an application of N-(4-(3- chlorine-4-(3-fluorine-benzyloxy) phenyl amidocyanogen]-quinazoline-6-radical-}-acrylamide or N-(4-(3-chlorine-4-(3-fluorine-benzyloxy) phenyl amidocyanogen)-7-methoxy-quinazoline-6- radical-)-acrylamide in preparing an antineoplastic, in particular to the application in preparing the antineoplastic for treating highly expressed epidermal growth factor receptor. The compound general formula I particularly provides an application of the general formula I compound in preparing drugs for treating erb-B2 highly expressed tumors, such as erb-B2 highly expressed lung cancer, ovarian cancers and breast carcinoma, etc.

Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

The invention discloses compounds represented by a general formula (I) shown in the description, wherein in the formula (I), A and B are respectively a six-membered cyclic compound containing D1, D2,D3 and D4 and a six-membered cyclic compound containing D5, D6, D7 and D8. The invention also disclose an indoleamine-2,3-dioxygenase and / or tryptophan-2,3-dioxygenase inhibitor containing the above compounds and the application of the compounds in preparation of medicaments for treating cancers. The compounds provided by the invention can effectively inhibit cell proliferation, and have good therapeutic effects on various diseases such as the cancers, significant therapeutic effects on breast cancer, cervical cancer, colon cancer, lung cancer, stomach cancer, rectal cancer, pancreatic cancer,brain cancer, skin cancer, oral cancer, prostate cancer, bone cancer, kidney cancer, ovarian cancer, bladder cancer, liver cancer, fallopian tube tumors, ovarian tumors, peritoneal tumors, stage IV melanoma, glioma, neuroblastoma, hepatocellular carcinoma, mastoid renal tumors, head and neck tumors, leukemia, lymphoma, myeloma and non-small cell lung cancers, and very broad application prospects.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

The invention discloses a Chinese medicinal composition for preventing or treating ovarian cancer, and relates to the technical field of Chinese medicaments. The Chinese medicinal composition is prepared from the following active components in parts by weight: 10 to 15 parts of golden cypress, 10 to 15 parts of burdock, 15 to 20 parts of fructus forsythiae, 15 to 18 parts of dandelion, 12 to 16 parts of hemlock parsley, 12 to 16 parts of cassia twig, 10 to 15 parts of Chinese rhubarb, 14 to 18 parts of rehmannia, and 6 to 10 parts of leech. The Chinese medicinal composition disclosed by the invention has remarkable curative effect, low cost and hardly toxic or side effect, and can be combined with other treatment modes to achieve the aim of resisting ovarian cancer.

Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.

Methods for inhibiting the growth of ovarian cancer cells or other serosal cancer cells are disclosed. The method involves exposing the cells to a benzylidinebenzohydrazide of formula:wherein X is carbon or nitrogen.

The invention belongs to the field of biological immunochromatography detection methods and specifically relates to a nano selenium kit for quickly detecting HE4 and CA125 and a preparation method thereof. The kit is composed of a sample pad, a combined pad, a reaction pad, a water absorption pad and a PVC bottom plate, wherein a detection line T1 coated by an anti-CA125 antibody A2, a detection line T2 coated by an anti-HE4 antibody B2 and a quality control line C coated by goat anti-rat IgG are arranged on the reaction pad; by means of observing color development reaction of the detection lines, bedside quick screening diagnosis of early ovarian cancer can be achieved. The prepared nano selenium immunochromatography kit disclosed by the invention has the advantages of strong specificity,high sensitivity, good accuracy, convenience, quickness, small sample amount to be detected and suitability for screening, homelab and bedside quick detection of high-risk groups for ovarian cancer.